|
||
|
||
| [Home Page] [Previous Menu] [Search] |
B-GT/5: Regulatory and clinical data
(Authors: M. Sneyers and M. Goossens - Last revised:
February 28, 2006
)
Title |
Pilot study of immunization with recombinant canarypox virus vCP1469A expressing the MAGE-1.A1 and MAGE-3.A1 cytolytic T lymphocytes epitopes in patients with malignant melanoma, non-small cell lung carcinoma, head-and-neck squamous cell carcinoma, esophageal squamous cell carcinoma or bladder carcinoma |
Company or sponsor |
Pasteur Mérieux Connaught |
Pharmaceutical study code |
MEL01198 |
Phase |
I |
Unicenter/multicenter study |
multicenter |
| Clinical data | see table 2 |
Installation |
Cliniques Universitaires St-Luc, Brussels |
Authorisation procedure |
contained use, new operation (see relevant regulation) |
Application number |
SBB 219 98/0215 |
User(s) |
Dr M. Marchand |
Receipt date |
26/03/1998 |
Biosafety Council meeting date |
14/04/1998 |
Authorisation date |
09/06/1998 |
Status |
trial completed |
|